SES
3.11.2020 08:52:12 CET | Business Wire | Press release
SES today announced Gilat and ST Engineering iDirect as its latest technology partners who will be developing the core infrastructure modem platforms for O3b mPOWER , SES’s ground-breaking non-geostationary-satellite orbit (NGSO) communications system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102006117/en/
Gilat and ST Engineering iDirect were selected based on their next-generation modem technologies. Featuring open architectures with a path to full virtualisation, the modems will interface with SES’s differentiated Adaptive Resource Control (ARC) capability and leverage SES’s use of the Open Networking Automation Platform (ONAP) standard. The combination of this and other technologies will give SES the ability to dynamically control and optimise the entire O3b mPOWER system across space and ground infrastructure, enabling the efficient delivery of low-latency and high-throughput satellite-based data services that can be truly customised to fit specific connectivity requirements on land, at sea or in the air anywhere in the world.
O3b mPOWER is SES’s next-generation medium Earth orbit (MEO) communications system. It is currently under construction and on track for launch in 2021. The high-throughput satellites, as well as automated and intelligence-powered ground infrastructure, will deliver low-latency managed services from hundreds of Mbps up to multiple Gbps.
"We are honoured to have been selected by SES, our long-time strategic partner, to provide our next-generation baseband platform for O3b mPOWER. Gilat's innovative ground segment significantly reduces cost-per-bit, delivers a step-change in modem performance, and further integrates with and optimises SES ground and space service delivery," said Ron Levin Vice President Mobility and Global Accounts at Gilat. "Throughout the last year, we have been working closely with SES to develop the platform for O3b mPOWER with the joint goal of bringing to market unparalleled customer experience in all target verticals.”
“We are at the beginning of a new future for our industry. To be selected for O3b mPOWER is a tremendous validation of ST Engineering iDirect's technology vision and proves that ground infrastructure will play a pivotal role in SES’s ambitious goal to transform satellite service delivery,” said Frederik Simoens, CTO, ST Engineering iDirect. “O3b mPOWER is at the forefront of a significant movement to drive a standards-based, virtualised network approach where ground is in lockstep with space. Through our partnership, we will greatly expand the possibilities for global connectivity.”
“The basis of our O3b mPOWER communications system is defined and advanced by a diverse and robust partner ecosystem. As an industry, we are able to embrace the vision of open networking and seamless satellite services because of like-minded partners such as Gilat and ST Engineering iDirect who understand the step-change in system flexibility and capacity that O3b mPOWER will deliver,” said Stewart Sanders, SES’s Executive Vice President of Technology and O3b mPOWER programme manager. “We have first-hand experience over many years of working with both Gilat and ST Engineering iDirect and have always been impressed with their work as well as what their technologies can provide. Hence, we have full confidence in selecting these two outstanding companies as trusted partners for O3b mPOWER and to deliver a key part of our infrastructure supporting an unparalleled customer experience.”
Focused on making satellites a seamless part of global network solutions, SES has been steadily expanding its O3b mPOWER partner ecosystem. In addition to Gilat and ST Engineering iDirect, SES has also announced O3b mPOWER partnerships with SpaceX for launches, ALCAN, Isotropic Systems and Viasat for customer edge terminals, Amdocs for NFV technology, Kythera Space Solutions for the ARC software, Microsoft for gateways , and IBM and Microsoft for cloud connectivity.
Follow us on:
Social Media
Blog
Media Library
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102006117/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
